Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Green IDs New Corn microRNAs


Rosetta Genomics subsidiary Rosetta Green said this week that it has discovered new corn plant microRNA sequences that “may contribute to improved tolerance to environmental stress, including resistance to salinity and temperature, as well as increased fertilizer use efficiency.”

The company said that these miRNAs may prove commercially valuable “since corn is one of the most common crops in the world, with its seeds being used for both human and animal consumption, as well as for production of alternative fuels.”

Rosetta Green was established in late 2008 as a unit of Rosetta Genomics as part of a bid to realize additional value from the company's miRNA technologies and know-how in areas outside of human health (GSN 10/30/2008).

In mid-2010, Rosetta made Rosetta Green a majority-owned subsidiary and passing along licenses to intellectual property related to the use of miRNAs in agricultural and clean technology applications (GSN 6/3/2010).

Earlier this year, the company went public on the Tel Aviv Stock Exchange (GSN 2/24/2011).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.